Systematic Review and Single-Arm Meta-Analysis of Bevacizumab Combined with Chemotherapy or Immunotherapy for Oncological Outcomes in Advanced/Recurrent Ovarian Clear Cell Carcinoma

The study aimed to evaluate the oncological outcomes related to bevacizumab-based combination therapy among patients with advanced or recurrent ovarian clear cell carcinoma (OCCC). PubMed, Web of Science, Cochrane Library and Embase were searched, and the Newcastle-Ottawa Scale (NOS) was utilized to assess the study quality. Results showed that bevacizumab significantly improved overall survival (OS) (HR = 0.51; 95% CI: 0.40-0.66) and progression-free survival (PFS) (HR = 0.42; 95% CI: 0.29-0.60). The overall objective response rate (ORR), complete response (CR), and partial response (PR) were 49% (95% CI: 39-60%), 17% (95% CI: 9-25%), and 31% (95% CI: 22-41%). Bevacizumab-based combination therapy may be a prospective strategy for advanced or recurrent OCCC.